Blackthorn Therapeutics Inc., a San Francisco-based company seeking traction for a high-tech approach to targeted mental health therapy, has closed a $76 million series B financing expected to help carry a mood disorder program into phase II later this year and move an autism-focused asset into the clinic. Both new and previous investors backed the round.